Short course of clarithromycin in an immunocompetent patient with BCG-induced regional complications

Dermatol Online J. 2002 Oct;8(2):6.

Abstract

Bacillus Calmette Guerin (BCG) has been used to vaccinate against tuberculosis since 1921. Persistant skin and lymph node lesions yielding Mycobacterium bovis are a rare complication for which there is not standardized treatment. We report an 11 month old child with a progressive cutaneous nodule and lymphadenopathy after BCG vaccination. These rapidly cleared with administration of clarithromycin.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • BCG Vaccine / adverse effects*
  • BCG Vaccine / therapeutic use
  • Clarithromycin / administration & dosage
  • Clarithromycin / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Humans
  • Immunocompetence*
  • Infant
  • Lymphatic Diseases / drug therapy*
  • Lymphatic Diseases / etiology
  • Lymphatic Diseases / microbiology
  • Mycobacterium bovis / immunology
  • Mycobacterium bovis / isolation & purification
  • Mycobacterium bovis / pathogenicity
  • Skin Diseases / drug therapy*
  • Skin Diseases / etiology
  • Skin Diseases / microbiology
  • Tuberculosis / prevention & control

Substances

  • BCG Vaccine
  • Clarithromycin